Inhibikase Therapeutics, Inc. 1Q 2026: Revenue $0 Net income $(16.4) M, EPS $(0.10) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Inhibikase Therapeutics, Inc. reported no revenue for Q1 2026, with a net loss of $(16.4) M, widening from $(13.7) M a year earlier. Diluted EPS was $(0.10), an improvement from $(0.15) in Q1 2025. The company initiated a Phase 3 study for IKT-001 and is pursuing regulatory approvals in over 25 countries. Increased R&D spending is noted, with a funding runway expected to last at least 12 months as the company raises capital through an ATM program.
Inhibikase Therapeutics, Inc. reported results for the first quarter of 2026, posting no revenue, a net loss of $(16.4) M versus a $(13.7) M loss a year earlier, and diluted loss per share of $(0.10) compared with $(0.15) in 1Q 2025.
Financial Highlights
- Revenue was $0 for 1Q 2026, unchanged from $0 in 1Q 2025.
- Net income was a loss of $(16.4) M for 1Q 2026, compared with a $(13.7) M loss in 1Q 2025; net loss widened by $2.7M, or 19.8% YoY.
- Diluted EPS was $(0.10) for 1Q 2026, versus $(0.15) in 1Q 2025.
Business Highlights
- Clinical milestone: Initiated the pivotal global Phase 3 IMPROVE-PAH study; first patient enrolled in April 2026 and sites activating across 16 countries.
- Regulatory progress: Pursuing approvals in 25+ countries and leveraging the FAST-EU pilot to accelerate multinational trial starts in Europe.
- R&D and pipeline: Advancing IKT-001 (an imatinib prodrug) for pulmonary arterial hypertension; completed non-human primate safety and bioequivalence studies.
- Operational posture: Increased R&D and SG&A spending to support Phase 3 and commercialization readiness; disclosed CRO/CMO commitments of approximately $67.6M through 2030.
- Funding runway: Cash and marketable securities expected to support operations for at least 12 months; company is raising capital via an ATM program and prior public/private financings to fund trials.
Original SEC Filing: Inhibikase Therapeutics, Inc. [ IKT ] - 10-Q - May. 12, 2026